BioSpace News Archive

- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into a $25 million convertible debt financing a

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Affairs has agreed to sponsor a quadruple blind, randomized, sham-controlled clinical trial of non-invasive vagal nerve stimulation (nVNS) in mild traumatic brain injury (mTBI) and Post-Traumatic Stress Disorder (PTSD). The trial is being sponsored by the Department of Veterans Affairs (VA) Office of Researc

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has reached a settlement agreement with Teva Pharmaceutical USA, Inc. (Teva) that resolves patent litigation brought in response to Teva’s Abbreviated New Drug Application (ANDA), seeking approval to market a generic version of Xtampza ER prior to the expiration of Collegium

Harrow Health, Inc. announced the appointment of Larry Van Horn to its Board of Directors.

Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg (LYTENAVA™) for use in retinal indications (known as ONS-5010). Outlook Therapeutics is advancing on multiple fronts, including: progress on its Phase 3 clinical program, manufacturing and regulatory activities, and global strategic partnering negotiations, all lead

- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors and tumor metastases, today announced that a virtual poster presentation has been accepted for the AACR Conference on Tumor Immunol

Emerging health threats, uncured diseases and the need to deliver critical therapies to patients are driving biotech companies to search for ways to build flexibility into their complex product pipelines and deliver projects in record time.

Allergan Aesthetics, an AbbVie company, announced the launch of SkinMedica® TNS® Advanced+ Pro-Infusion Serum for DiamondGlow™ treatments.

Vexos Inc., a Global Electronics Manufacturing Services provider, is pleased to announce that Health Canada has approved the Mechanical Ventilator Milano (MVM) ventilator for use under Interim Order. In May, Vexos signed a contract with the Government of Canada to manufacture and supply 10,000 MVM units as part of the national mobi

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today